1xbet 카지노., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the comprehensive genomic profiling assay 1xbet 카지노 hematologic malignancies, developed by Otsuka and the National Cancer Center Japan, has been granted the SAKIGAKE designation by Japan's Ministry of Health, Labour and Welfare.

An evaluation of this assay is underway by a consortium compris1xbet 카지노g the National Cancer Center Japan and several major medical facilities 1xbet 카지노 Japan.

The SAKIGAKE (1xbet 카지노erunner initiative) Designation System aims to advance early practical applications 1xbet 카지노 innovative new medicines and other products. In principle, designated product must have the potential 1xbet 카지노 novel treatment effectiveness or reduction in symptoms based on a different mechanism of action from already approved products. Designated products are eligible 1xbet 카지노 prioritized consultation services and reviews 1xbet 카지노 regulatory authorizations.

This is the first comprehensive genomic profiling assay developed in Japan 1xbet 카지노 hematologic malignancies. Unlike existing gene panel tests 1xbet 카지노 solid tumors, 1xbet 카지노 this assay DNA and RNA extracted from peripheral blood, bone marrow fluid, lymphoid tissue, etc. are used as measurement samples. Clinically useful genetic abnormalities in hematopoietic tumors are detected based on the Hemotological Society of Japan'sHematopoietic Cancer Genome Test1xbet 카지노g Guidel1xbet 카지노es.

This assay covers almost all categories of hematologic malignancies: myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm; lymphoid malignancies such as acute lymphoblastic leukemia, lymphoma, and myeloma; and congenital bone marrow failure syndromes. This assay will provide a valuable in1xbet 카지노mation 1xbet 카지노 clinicians and patients in diagnosis, treatment, and prognostic prediction.